Overview

ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment

Status:
Completed
Trial end date:
2015-03-30
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well ABT-751 works in treating children with neuroblastoma that has relapsed or not responded to previous treatment. Drugs used in chemotherapy, such as ABT-751, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Phase:
Phase 2
Details
Lead Sponsor:
Children's Oncology Group
Collaborator:
National Cancer Institute (NCI)